All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Orphan drug designation granted to MB-105 for the treatment of R/R T-cell lymphoma
On January 29, 2025, the U.S. Food and Drug Administration (FDA) granted orphan drug designation to MB-105, a first-in-class autologous CD5-targeted CAR T-cell therapy, for the treatment of relapsed/refractory (R/R) T-cell lymphoma.1
This announcement is based on key results from a phase I MB-105 (NCT03081910) trial, which demonstrated favorable safety/tolerability and promising clinical efficacy of MB-105 in patients with R/R T-cell lymphoma (N = 17), with an overall response rate of 44%.1,2
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
